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Distal symmetric polyneuropathy is a common complication
of diabetes and a major cause of diabetic foot ulcers [1,2].
When diagnosing neuropathy, the San Antonio Consensus
recommended at least one measurement in five different
diagnostic categories [3], including symptoms. Symptom scores
should fulfil the criteria as described by Jaeschke, including
validation (independent reference standard, adequate spectrum
and number of patients, standardization, soundly based item
selection), predictive value and practicality (reproducibility,
performance in clinical practice) [4].
Several symptom scores have been developed to assess
symptoms of diabetic neuropathy, including the Neuropathy
Symptom Score (NSS) [5—8]. The latter has been widely studied
and is known to be valid and sensitive. It is extensively used
in clinical practice. Several adaptations are available such as
the Neuropathy Symptom Profile, the Michigan Neuropathy
Screening Instrument (MNSI) and the modified NSS scores of
Veves and Young [9—12]. However, none of these scoring
systems fulfils all JaeschkeÕs diagnostic criteria. Our aim was
to validate a new, four-item Diabetic Neuropathy Symptom
(DNS) score for diagnosing distal neuropathy in diabetes, and
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To provide one of the diagnostic categories for distal diabetic polyneuro-
pathy, several symptom scoring systems are available, which are often extensive
and lack in validation. We validated a new four-item Diabetic Neuropathy Symptom




We compared score characteristics of the generally accepted
Neuropathy Symptom Score (NSS) with the DNS score, and tested construct
validity, predictive value and reproducibility with the Diabetic Neuropathy
Examination score, Semmes—Weinstein monofilaments and Vibration Perception
Threshold (clinical standards) in 73 patients with diabetes (24 Type 1, 49










Patient scores were more differentiated on the DNS score. The relation of the












The DNS is validated, fast and easy to perform, with a high
predictive value when screening for diabetic polyneuropathy.
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We studied 73 patients with diabetes, covering the entire
spectrum of secondary complications. Informed consent was
obtained. Exclusion criteria were factors which may have
interfered with the neurological condition other than neuro-
pathy. Fifty patients were randomly selected from the diabetes
out-patient clinic of the University Hospital Groningen. The
other 23 all had obvious diabetic foot complications or clinical
neuropathy, and attended the Rehabilitation Centre Beatrix-




The same researcher (J.W.G.M.) examined all 73 individuals.
The symptom scores were obtained first, followed by clinical
standards: a physical examination score (the Diabetic Neuro-
pathy Examination (DNE) score) and quantitative sensory tests
(Semmes—Weinstein Monofilaments (SW-MF) and Vibration






 The NSS consists of 17 items, eight focusing on muscle
weakness, five on sensory disturbances and four on autonomic symp-
toms [5,6]. Items that are answered negative/absent are scored




 An expert panel developed a four-item symptom
score for diabetic neuropathy, consisting of a diabetologist, a
vascular internist, a neurologist and a physician for rehabilita-
tion medicine. The DNS score has the following items: (i) un-
steadiness in walking, (ii) pain, burning or aching at legs or feet,
(iii) prickling sensations in legs or feet, and (iv) numbness in
legs or feet. Presence is scored 1, absence 0, maximum score





The DNE score, SW-MF and VPT were chosen as clinical





 This is a validated, hierarchical physical exam-
ination score, identifying distal symmetric polyneuropathy [13]. It
exists of eight items, two testing muscle strength, one a tendon
reflex, and five sensation. The maximum score is 16. A score




 These were tested on the
plantar surface of the hallux and centrally at the heel (when
necessary after removal of excessive callus), using standard
guidelines [14—17]. We used the Ôyes—noÕ method, meaning that
the patient says yes each time he/she senses the application of
a monofilament. Six trials were taken; when the patient was
unable to respond correctly in more than one trial, a heavier
monofilament was taken. The 1, 10 and 75-g monofilaments





 VPT was tested using a
hand-held biothesiometer at the dorsum of the hallux on the
interphalangeal joint and at the lateral malleolus [18—20]. The
voltage of vibration was increased until the patient could
perceive vibration on three occasions. The mean of these was used
to determine the VPT. Age-adjusted reference values were used













To test reproducibility of the DNS score, inter- and intra-rater
agreement was assessed in a separate study on 10 patients. The





had a wide range of neuropathy severity. The mean duration





participants had Type 1, and seven Type 2 DM. Two doctors


















. The statistical package SPSS-PC was used













-test and ROC curves [21].













) of 1.9 (2.0), and
1.1 (1.3), respectively. The reliability of the DNS score (0.64) was











Relationship of NSS and DNS with the clinical standards
 




 for the DNE score with




 < 0.001), respectively. Scores between the monofilament, NSS




 < 0.05), respect-




 < 0.001), respectively.
Table 1 Patient characteristics
n 73
Mean age (years) (SD) 56.9 (16.1)
Min.—max. (years) 19—90
Mean duration DM (years) (SD) 14.9 (9.9)
Min.—max. (years) 1—43
Sex, male—female 43—30
Type DM 1—2 24—49




Peripheral vascular disease, % 38
Present or former ulcer, % 20
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Figure 1 shows the ROC curves of the NSS and DNS, respect-
ively, compared with the DNE. The areas under the curve
are 0.75 and 0.78 for NSS and DNS, respectively. Using the
monofilament at the hallux these values were 0.62 and 0.65,
respectively; and using VPT 0.68 and 0.73.
At a cut-off point of 0 vs. 1—4 for the DNS, sensitivity was
79% and specificity 78%, using the DNE. With the monofila-
ment, sensitivity was 81% and specificity 56%, and VPT 81%
and 58%, respectively.




for both raters of 0.89 and 0.78, the inter-rater agreement on
two occasions was 0.95 and 0.83, respectively, indicating a




The DNS and NSS scored similarly and both fulfil the Jaeschke
criteria for diagnostic tests. Although the NSS has been
validated previously and is widely accepted, it is probably too
extensive to be used in every day clinical practice to diagnose
neuropathy. Other, shorter scoring systems and modifications
do not appear to fulfil the criteria for diagnostic tests. Thus, we
propose the four-item DNS score as a fast and easy to perform
symptom score with high reproducibility. The DNS has been
validated using standard clinical methods, but might be too
short to provide reliable follow-up when used alone.
Sensitivity and specificity of the DNS score were high when
defined using other standard methods for evaluating
neuropathy. Because the DNS score will be used for screening
purposes, a high sensitivity is to be preferred. A score of 1 or
more points on the DNS score is sensitive when identifying
neuropathy. In combination with the results of the other
diagnostic categories, classified by the San Antonio Consensus,
the type and severity of neuropathy can be estimated. Unfor-
tunately, the relative importance of different categories of the
San Antonio Consensus in diagnosing diabetic neuropathy
and predicting diabetic foot complications is unknown.
Controversy exists about the use of symptom scoring in
diagnosing diabetic neuropathy [7,24—27]. In our report,
significant and clinically relevant correlations were shown
between the symptom scores and other methods which can
predict diabetic foot complications. We believe that symptom
scoring should complement other diagnostic categories for
diabetic neuropathy [3].
However, symptom scores may be less reliable [3,4,8], due
to their subjectivity. Using dichotomous scores may improve
reproducibility [3], a feature of the DNS.
In conclusion, the DNS has been validated for cases of
diabetic polyneuropathy, and is fast and easy to perform in
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Table 2 The relation of clinical standards to symptom scores
DNE score
  SW-MF hallux
VPT hallux
n Mean NSS (SD) Mean DNS (SD)
0 24 0.92 (1.47) 0.42 (0.93)
1 48 2.42 (2.07) 1.52 (1.24)
P = 0.002 P = 0.000
n Mean NSS (SD) Mean DNS (SD)
0 45 1.42 (1.42) 0.84 (1.04)
1 25 2.64 (2.63) 1.56 (1.41)
P = 0.014 P = 0.019
n Mean NSS (SD) Mean DNS (SD)
0 39 1.28 (1.47) 0.67 (0.98)
1 32 2.63 (2.34) 1.69 (1.30)
P = 0.004 P = 0.000
Group 0, Normal on clinical standard; group 1, disturbed on 
clinical standard.
Figure 1 ROC curves of NSS and DNS scores in relation to the DNE 
score.
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 Human diabetic endoneurial sorbitol, fructose and
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Appendix 1 DNS score
 
The questions should be answered ÔyesÕ (positive: 1 point) 
 
if a symptom occurred more times a week during the last 2 weeks
 
 or ÔnoÕ 
(negative: no point) 
 






1 Are you suffering of unsteadiness in walking?
 
need for visual control, increase in the dark, walk like a drunk man, lack of contact with floor
 
2 Do you have a burning, aching pain or tenderness at your legs or feet?
 
occurring at rest or at night, not related to exercise, exclude claudicatio intermittens
 
3 Do you have prickling sensations at your legs and feet?
 
occurring at rest or at night, distal>proximal, stocking glove distribution
 
4 Do you have places of numbness on your legs or feet?
 
distal>proximal, stocking glove distribution
 
Maximum score: 4 points; 0 points, PNP absent; 1—4 points, PNP present.
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